CIK 0001750149
- Non-accelerated filer
- Smaller reporting company
Inhibikase Therapeutics, Inc.
Sign in to watch- Ticker
- IKT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 263407249
- Phone
- +1 302-295-3800
- Business address
- 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-21 | Cabell Christopher President & Head of R&D | Returned to the company | −338,282 | 676,564 | ||
| 2026-01-05 | Cabell Christopher President & Head of R&D | Grant or award · Stock Option (Right to Buy) | +900,117 | 900,117 | ||
| 2025-02-21 | Cabell Christopher President & Head of R&D | Grant or award · Stock Option (Right to Buy) | +1,100,705 | 1,100,705 | ||
| 2025-02-21 | Cabell Christopher President & Head of R&D | Grant or award · Stock Option (Right to Buy) | +1,100,705 | 1,100,705 |
Page 1 of 1 · 4 trades